1	Confounder-adjusted MRI-based predictors of multiple sclerosis disability
2	Yujin Kim, B.S. <sup>1</sup> , Mihael Varosanec, M.D. <sup>1</sup> , Peter Kosa, Ph.D.1, Bibiana Bielekova, M.D. <sup>1*</sup> .
3	
4	<sup>1</sup> National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory
5	of Clinical Immunology and Microbiology, Neuroimmunological Diseases Section, Bethesda,
6	MD, 20892, USA
7	
8	* Correspondence: Bibiana Bielekova, Neuroimmunological Diseases Section (NDS), National
9	Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH),
10	Building 10, Room 5N248D, Bethesda, Maryland 20892. E-mail: <u>bibi.bielekova@nih.gov</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 11 ABSTRACT

Introduction: Both aging and multiple sclerosis (MS) cause central nervous system (CNS) 12 13 atrophy. Excess brain atrophy in MS has been interpreted as accelerated aging. Current paper 14 tests an alternative hypothesis: MS causes CNS atrophy by mechanism(s) different from physiological aging. Thus, subtracting effects of physiological confounders on CNS structures 15 16 would isolate MS-specific effects. 17 Methods: Standardized brain MRI and neurological examination were acquired prospectively in 18 649 participants enrolled in Clinical Trials.gov Identifier: NCT00794352 protocol. CNS volumes 19 were measured retrospectively, by automated Lesion-TOADS algorithm and by Spinal Cord 20 Toolbox, in a blinded fashion. Physiological confounders identified in 80 healthy volunteers 21 were regressed out by stepwise multiple linear regression. MS specificity of confounder-adjusted 22 MRI features was assessed in non-MS cohort (n=160). MS patients were randomly split into 23 training (n=277) and validation (n=132) cohorts. Gradient boosting machine (GBM) models 24 were generated in MS training cohort from unadjusted and confounder-adjusted CNS volumes 25 against four disability scales. 26 **Results:** Confounder adjustment highlighted MS-specific progressive loss of CNS white matter. 27 GBM model performance decreased substantially from training to cross-validation, to 28 independent validation cohorts, but all models predicted cognitive and physical disability with 29 low p-values and effect sizes that outperforms published literature based on recent meta-analysis. 30 Models built from confounder-adjusted MRI predictors outperformed models from unadjusted 31 predictors in the validation cohort.

32	Conclusion: GBM models from confounder-adjusted volumetric MRI features reflect MS-
33	specific CNS injury, and due to stronger correlation with clinical outcomes compared to brain
34	atrophy these models should be explored in future MS clinical trials.
35	
36	Keywords
37	Magnetic resonance imaging, physiological confounders, multiple sclerosis, disability outcomes,
38	machine learning, gradient boosting machine
39	
40	Highlights
41	• Regressing out physiological confounders affecting volume of CNS structures in healthy
42	volunteers, strengthened correlations between white matter volumes and disability
43	outcomes in MS cohorts
44	• Aggregating volumetric features into generalized boosting machine (GBM) models
45	outperformed correlations of individual MRI biomarkers with clinical outcomes in MS
46	• Developed more sensitive and reliable models that predict MS-associated disability
47	• Independent validation cohorts show true model performances
48	• Developed GBM models should be explored in future MS clinical trials
49	
50	Data Availability
51	All raw data and script used for all analyses will be provided after being accepted.
52	
53	Author Contribution

54	YK and MV performed MRI scan processing, volumetric analyses, and maintained the cloud
55	based QMENTA platform to generate brain volumetric data. YK performed all analyses detailed
56	in the paper, generated the figures, and contributed to writing the paper. PK exported all clinical
57	scores used in correlation analyses and supervised in the development of GBM models. BB
58	construed the project conceptually, guided and supervised all aspects of the study, and
59	contributed to the writing of the paper and figure creations. All authors critically reviewed and
60	edited the manuscript.
61	
62	Acknowledgements
63	We are grateful for all study participants as well as everyone in the Clinical Immunology and
64	Microbiology (LCIM) for their support and feedbacks.
65	
66	Funding
67	The research was supported by the Intramural Research Program of the National Institute of
68	Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
69	
70	Conflict of Interest

71 The authors declare no conflict of interest.

# 72 1. INTRODUCTION

73	Scientific advancements in Multiple Sclerosis (MS) translated into the development of disease-
74	modifying treatments (DMTs) that effectively inhibit central nervous system (CNS) tissue
75	destruction and clinical disability development if given to a young subject shortly after disease
76	onset. Unfortunately, these treatments lose efficacy with advancing age of patients. On a group
77	level, they show no statistically-significant inhibition of disability progression in subjects older
78	than 54 years (Weideman et al., 2017b). To develop more effective MS treatments, we need
79	sensitive outcomes that can objectively quantify CNS tissue destruction and development of
80	disability against active comparator, in reasonably sized cohorts.
81	
82	Magnetic resonance imaging (MRI) volumetric outcomes such as brain atrophy, have been
83	successfully used in Phase II and Phase III MS clinical trials (Hemond and Bakshi, 2018; Jacobs
84	et al., 2021; Zeydan and Kantarci, 2020). However, is brain atrophy the most sensitive and the
85	most specific imaging outcome in MS?
86	
87	In terms of sensitivity, there is mounting evidence that atrophy of deep gray matter (GM)
88	structures, especially thalamus (Amin and Ontaneda, 2021), or enlargement of ventricles
89	(Jakimovski et al., 2020) may exert larger effect sizes in MS than whole brain atrophy.
90	Additionally, assembling several of these changing brain volumes into a single model using
91	machine-learning (ML) algorithm(s) may further increase effect size.
92	
93	In terms of specificity, brain atrophy also occurs during natural aging (Rocca et al., 2017). In
94	what we identified as the largest published study of healthy volunteers (HV; n=2790),

95	physiological confounders such as age, gender and predicted intracranial volume (PIV),
96	explained a very high proportion of variance in thalamic (>60%), caudate (>40%) and
97	ventricular (57%) volumes (Potvin et al., 2016). In fact, ML-derived models can predict
98	chronological age (with a mean absolute error of +/-5 years (Cole et al., 2017)) using just brain
99	MRI predictors. A study from European Magnetic Resonance Imaging in MS (MAGNIMS)
100	consortium (Cole et al., 2020) explored the difference between chronological and brain MRI-
101	predicted age, termed as Brain-predicted Age Difference (Brain-PAD). The study demonstrated
102	that 1204 MS patients had on average 6 years higher Brain-PAD compared to HV, without
103	significant differences among MS subtypes (i.e., relapsing-remitting [RRMS], secondary-
104	[SPMS] and primary-progressive MS [PPMS]). Brain-PAD also correlated with disability
105	measured by Expanded Disability Status Scale (EDSS). Although no effect size was provided,
106	the associated figures suggested that Brain-PAD explains < 10% of EDSS variance. The authors
107	concluded that MS is associated with accelerated brain aging (Cole et al., 2020).
108	
109	It could be alternatively interpreted that MS and natural aging destroy structurally overlapping
110	CNS areas, but MS does so by different pathophysiological processes. This interpretation may
111	explain why treated MS patients had significantly higher Brain-PAD compared to untreated MS
112	patients (Cole et al., 2020). If MS causes accelerated brain aging and MS DMTs inhibit MS-
113	associated CNS damage, then treated MS patients should have decreased Brain-PAD, not
114	increased. On the other hand, if MS and natural aging cause CNS damage by different

115 mechanisms, then MS DMTs may have none, or even paradoxical effect(s) on Brain-PAD. Our

116 previous study demonstrated that CSF biomarkers also predict chronological age in HV with

117 high accuracy. When we applied this model to MS patients, we saw no significant differences in

age-predictions between HV and MS (Barbour et al., 2020). These data strongly support this
alternative interpretation, in which (molecular) mechanisms of aging and MS progression are
mostly different.

121

- 122 Further extension of this interpretation is the hypothesis that aging process and other
- 123 physiological confounders reflected on volumetric brain MRI represent "noise" when trying to
- 124 understand (and treat) MS-specific processes. Here, we examine this hypothesis by addressing
- the following aims: (1) To adjust volumes of the CNS structures for physiological confounders
- identified from internal HV cohort to understand effects of MS on CNS structures; (2) To
- 127 examine, whether confounder-adjusted MRI predictors can be assembled into computational
- 128 models that predict clinical disability in the independent validation cohort, and whether such
- validated model exerts larger effect size(s) than any single MRI biomarker; (3) To investigate
- 130 whether computational model(s) derived from confounder-adjusted MRI predictors outperform
- 131 models(s) from raw MRI volumes in predicting clinical disability outcomes.

132

### 133 2. MATERIAL AND METHODS

134 The study design is shown in Figure 1.

135

### **136 2.1 Cohort characteristics**

137 All patients were prospectively recruited into the protocol "Comprehensive Multimodal Analysis

138 of Neuroimmunological Diseases of the Central Nervous System" (Clinicaltrials.gov Identifier:

139 NCT00794352) and provided written informed consent. The inclusion criteria for patient cohort

are age at least 12 years and clinical symptoms, CSF results or MRI imaging suggestive of

141	neuroimmunological disease. Approximately 60% of enrolled patients eventually fulfill
142	contemporary version of MS diagnostic criteria (with all 3 MS subtypes represented), while 20%
143	have other inflammatory neurological diseases (OIND) and 20% have non-inflammatory
144	neurological diseases (NIND). The HV inclusion criteria are age at least 18 years, absence of
145	known diseases and conditions that could affect CNS and normal vital signs at the screening
146	visit. The protocol was approved by the Combined Neuroscience Institutional Review Board of
147	the National Institutes of Health. Patient demographics and other clinical characteristics are
148	provided in Supplementary Figure S1.
149	
150	All subjects (n=649) with brain MRI images that passed quality control (see below) and had
151	matched clinical outcomes were included. Neurological exams documented in structured
152	electronic medical record note were either transcribed (before 2017) or directly documented
153	(after 2017) into the NeurEx <sup>TM</sup> App (Kosa et al., 2018) by clinicians with MS specialization. The
154	NeurEx <sup>TM</sup> App automatically computes MS disability scales including EDSS (Kurtzke, 1983)
155	(ordinal scale from 0-10) and NeurEx (continuous scale from 0 to theoretical maximum of 1349).
156	
157	Functional tests (i.e., timed 25 foot walk and 9 hole peg test) are required for computing of
158	Combinatorial weight-adjusted disability score (CombiWISE; continuous scale from 0-100)
159	(Weideman et al., 2017a), and Symbol Digit Modalities Test (SDMT) (Benedict et al., 2017).
160	These were acquired by investigators blinded to clinician-derived disability scales and were
161	recorded into research database.
162	

# 163 2.2 Volumetric Analysis

164	Investigators involved in MRI analysis were blinded to clinical outcomes and diagnostic
165	categories. MRIs were performed on two scanners: Signa (3TA, General Electric, Milwaukee,
166	WI) using 16-channel head coil and Skyra (3TD, Siemens, Malvern, PA) using 32-channel head
167	coil. Sequences included 3D-MPRAGE (TR, 3000 ms; TE, 3 ms; TI, 900 ms; FA 8°; 1-mm
168	isotropic resolution, TA 6 min), 3D-FLAIR (TR, 4800 ms; TE, 354 ms; TI, 1800 ms; 1-mm
169	isotropic resolution; acquisition time, 7 min), and PD/T2 (TR, 3540 ms; TE, 13 and 90 ms; 0.8-
170	mm in-plane resolution; slice thickness, 2 mm; acquisition time, 4 min) on 3TD and 3D-FSPGR-
171	BRAVO (TR, 1760 ms; TE, 3 ms; TI, 450 ms; FA 13°; 1-mm isotropic resolution; acquisition
172	time, 5 min), 3D-FLAIR-CUBE (TR, 6000 ms; TE, 154 ms; TI, 1800 ms; 1-mm isotropic
173	resolution; acquisition time, 9 min), and PD/T2 (TR, 5325 ms; TE, 20 and 120 ms; 1-mm in-
174	plane resolution; slice thickness, 3 mm; acquisition time 4 min) on 3TA. Sagittal and axial cuts
175	extended distally to C5 level, allowing determination of semi-qMRI biomarkers of
176	medulla/upper spinal cord (SC) atrophy using SC Toolbox (De Leener et al., 2017).
177	
178	After pre-processing steps (1. De-identification, 2. DICOM to NIFTI transformation, 3. Skull
179	stripping; and 4. Alignment), images were uploaded to commercial cloud-based imaging
180	platform QMENTA (https://www.qmenta.com/) which, in collaboration, implemented the
181	published Lesion-TOADS (Shiee et al., 2010) algorithm. Lesion-TOADS combines a topological
182	and statistical likelihood atlas for computation of 12 CNS volumetric biomarkers: Cerebral white
183	matter (WM), Cerebellar WM, Brainstem, Putamen, Thalamus, Caudate, Cortical gray matter
184	(GM), Cerebellar GM, Lesion Volume, Ventricular CSF and Sulcal CSF. Average cross-
185	sectional area (CSA) of the upper cervical SC at C1-C2 level was calculated using SC Toolbox
186	from 3D MPRAGE brain MRI images.

187

188	Before unblinding, we performed quality control of volumetric data. A total of 62 (8.7%) MRI
189	scans was excluded due to inaccurate segmentation of brain structures, low image quality, and
190	motion artifacts, leaving 649 scans for the final dataset in study.
191	
192	After unblinding diagnostic categories, MS patients were randomly split into training and
193	validation cohort (2:1 ratio) with equal proportion in gender and MS subtypes.
194	
195	2.3 Adjusting MRI biomarkers for healthy volunteers (HV) confounders
196	Using only the HV cohort (n=80), MRI volumes were adjusted for age, age^2, body mass index
197	(BMI), height, gender, and supratentorial intracranial volume using stepwise multiple linear
198	regression. Final linear regression models were applied to all subjects to regress out
199	physiological confounders. The example of confounder adjustments for ventricular volume is
200	shown in Figure 2. Supplementary information contains analogous data for all remaining MRI
201	biomarkers.
202	
203	The correlation between the confounders and individual structural volumes, before and after co-
204	variate adjustments, was evaluated using linear regression models in R Studio, reporting a
205	coefficient of determination ( $R^2$ ; the proportion of variance explained [ranging from 0 to 1] by
206	the linear model, where higher number signifies closer fit of experimental data points to the
207	linear regression line of the model), slope, and HV 95% confidence interval.
208	

209 Differences between HV and MS cohorts in unadjusted and confounder-adjusted MRI
210 biomarkers were analyzed using unpaired two-samples Wilcoxon signed-rank test in R (Team,
211 1969).

212

### 213 2.4 Gradient Boosting Machine (GBM) Modeling in the MS training cohort

214 Unadjusted or confounder-adjusted MRI biomarkers that showed statistically significant 215 difference between MS and HV in univariate analyses were used as predictors to model four 216 clinical outcomes: CombiWISE, EDSS, NeurEx, and SDMT. We selected a tree-based 217 supervised ML algorithm because we considered that MRI features may have non-linear effects 218 and patients may exert heterogeneity in which brain/SC structures are most affected by the 219 disease. Among tree-based algorithms, we selected GBM over Random Forest. While GBM is 220 more difficult to optimize (if using large number of predictors), it is believed to generally 221 outperform Random Forest. GBM builds trees sequentially, where each successive tree is built 222 using residuals from the previous tree's predictions. The predictions are iteratively updated by 223 adding the current tree's prediction (times a shrinkage parameter) to the previous tree's 224 prediction. For each tree constructed, an out-of-bag (OOB) sample containing half of the 225 observations is withheld from the training cohort to introduce randomness into the modeling 226 process. Main GBM tuning parameters are the depth of the individual trees (interaction depth), 227 the shrinkage parameter (learning rate), the minimum number of observations in trees' terminal 228 nodes, and the number of trees. Using the gbm R package (Greenwell et al., 2020), we selected 229 an interaction depth of 6, nodes of 5, a shrinkage parameter of 0.01, and used a 10-fold cross 230 validation to select the optimal number of trees that will prevent each model from overfitting. 231 Improvement in mean squared error from splits within each individual tree and the average of

these improvements across all trees in the ensemble calculated the relative influence of eachvariable in a model.

234

Each clinical scale was modelled separately since each assesses different attributes of the
neurological spectrum (e.g., SDMT measures reaction time reflective of cognitive disability
whereas other three scales reflect predominantly physical disabilities). The models were
optimized by observing the lowest root mean squared error in the combination of feature
selections within the MS training cohort.

241 2.5 GBM model validation

242 With the final optimized models, two validations methods were performed: (1) 10-fold cross-243 validation and (2) an independent cohort validation. 10-fold cross-validation reuses the training 244 cohort data by randomly partitioning the data into an "internal" training set (90% of the total 245 training cohort) and validation set (10% of the total training cohort) on different iterations. The 246 model then tests prediction accuracy of the withheld samples. However, the independent cohort validation strategy utilizes a completely new dataset that was removed before model 247 248 development. This allows true evaluation of the models' performances in predicting clinical 249 scores.

250

Correlations between measured and predicted clinical scores were evaluated using linear
regression models in R Studio version 4.1.0 (Team, 2015; Team, 2021), reporting R^2,
Spearman Rho (the relationship strength of the predicted and measured scores) from R CRAN
Package: stats (Team, 1969) and rstatix (Kassambara, 2021); and Concordance Correlation

- 255 Coefficient (CCC; the degree of reliability in the method when comparing two measurements of
- the same variable) from R CRAN Package: DescTools (Signorell et al., 2021).
- 257
- 258 Additional materials and methods are included as Supplemental text.
- 259

### **3. RESULTS**

### 261 **3.1 Regressing out physiological confounders**

262 We regressed out effects of physiological confounders based on internal HV cohort as described

in Methods and exemplified in Figure 2. For ventricular CSF volume, the multiple linear

regression model selected only effects of age<sup>2</sup> and intracranial volume from the 6 tested

265 confounders. For some other CNS structures, the multiple linear regression models were more

complex. But consistent with published studies, we saw no independent effects of BMI on any

267 CNS volume.

268

### 269 **3.2 MS-specific residual effects of age and gender on CNS volumes**

270 Several remaining confounding effects on GM volumes were noted in MS cohort. All GM

structures demonstrated same paradoxical trend of increasing GM volumes with age of MS

272 patients. This relationship reached statistical significance (i.e., Bonferroni adjusted p<0.004) for

273 caudate (R^2=0.04, p=0.002; Supplementary Figure S2A), cerebrum GM (R^2=0.06, p<0.001,

274 Supplementary Figure S2B), putamen (R^2=0.08, p<0.001; Supplementary Figure S2C) and

supratentorial GM (R^2=0.06, p<0.001, Supplementary Figure S2D). Since these residual effects

were not seen in non-MS cohort (Supplementary Figure S2), they are MS-specific and are driven

by non-physiologically low GM volumes in young patients. Although the unadjusted volumes of

278 these GM structures decrease with age (consistent with other longitudinal studies), the 279 paradoxical positive residual effect of age in MS emerges after subtracting physiological 280 confounders because the slope of age-related decrease is higher in HV and non-MS cohorts. 281 282 In contrast to GM where younger MS patients exhibited more profound non-physiological 283 atrophy compared to older MS patients, we observed residual linear loss of supratentorial WM 284 (R<sup>2</sup>=0.10; p<0.001; Supplementary Figure S3B) and normal appearing WM (R<sup>2</sup>=0.09; 285 p<0.001; Supplementary Figure S3A) with MS aging, paralleled by significant residual increase 286 in ventricular (but not sulcal) CSF volume (R^2=0.04; p=0.002, Supplementary Figure S4B). 287 This progressive non-physiological WM loss was MS specific (i.e., it was not observed in non-288 MS cohort) and affected also the cerebellum WM even though the residual correlation of 289 cerebellum WM with age in MS became non-significant after Bonferroni adjustment. In fact, the 290 large non-MS cohort (n=160) behaved identically to HV regarding all WM volumes, while it 291 exhibited non-physiological atrophy in some GM structures (including thalamus, Supplementary 292 Figure S4A) and non-physiological increase in ventricular volume (Supplementary Figure S4B). 293 294 We conclude that subtracting effects of physiological confounders on volumes of CNS structures 295 identified non-physiological loss of GM volumes in young MS patients and MS specific, 296 progressive non-physiological loss of WM volumes. 297 298 **3.3 Differences in unadjusted and confounder-adjusted MRI features between HV and MS** 299 As shown in Supplementary Figure S1, HV cohort was significantly younger than MS (i.e., 300 Median 40.4 years vs Median=52.4 years; p=1.24e-7). Because age exerted significant effects on

301	many CNS volumes, subtracting the variance explained by age diminished differences between
302	HV and MS cohorts in most CNS volumetric biomarkers (Figure 3). The greatest decrease in
303	effect size was seen for thalamus, caudate and brain parenchymal fraction (BPFr) - consistent
304	with the reported strong effect of physiological aging on these CNS structures.
305	
306	Unexpectedly, we observed increase in effect sizes of WM volumes on differentiating MS from
307	HV after confounder adjustment: Supratentorial WM and normal appearing WM (which are
308	highly correlated – see Figure 4) but marginally also cerebellum WM.
309	
310	Confounder adjustment affected correlations between MRI features (Figure 4). As expected, it
311	eliminated correlations of MRI biomarkers with age in the HV cohort. But the adjustment also
312	enhanced correlations of BPFr with most brain volumes in both HV and MS cohorts. Finally,
313	confounder adjustments strengthened correlations of brain WM volumes and ventricular CSF
314	with remaining MRI features in MS.
315	
316	3.4 Univariate correlations of MRI features with clinical outcomes
317	Figure 5 and Supplementary Table S1 show univariate Spearman correlation coefficients and p-
318	values of unadjusted and HV confounder-adjusted MRI volumes with clinical outcomes in the
319	MS training and validation cohorts. We observed that for physical disability outcomes (EDSS,
320	CombiWISE and NeurEx), age exerted comparable or higher effect size on clinical outcomes
321	than the strongest MRI biomarkers. This was not true for SDMT, where brain lesion volume and
322	ventricular CSF had strongest correlations.

323

324	As would be expected from strong univariate correlations of age with disability outcomes and
325	with MRI volumes, subtracting age effects significantly diminished correlations of CSF volumes,
326	GM volumes and even BPFr with clinical outcomes.
327	
328	However, confounder adjustment strengthened correlation of WM volumes with all clinical
329	outcomes (in both cohorts). In fact, WM volumes became the highest correlated MRI biomarkers
330	with physical disability outcomes (NeurEx and CombiWISE) and NAWM became the second
331	highest (after lesion volume) correlating biomarker with SDMT in the validation cohort after
332	confounder adjustment.
333	
334	We conclude that adjustment for physiological confounders reproducibly strengthened
335	correlations of supratentorial WM volumes with MS clinical outcomes.
336	
337	3.5 Models from MRI volumetric data adjusted for physiological confounders achieve
338	stronger effect sizes in predicting MS clinical outcomes in the independent validation
339	cohort
340	Unadjusted and confounder-adjusted MRI features that achieved statistical significance in
341	differentiating HV and MS cohorts were inputted into ML-based models of four clinical
342	outcomes. Because age and gender exerted significant influence on clinical outcomes and their
343	effects were subtracted from confounder-adjusted MRI volumes, we added these demographic
344	variables into the model that used adjusted MRI volumes. The full statistical results from all
345	models are in Supplementary Table S2.

346	For the three outcomes of physical disability (i.e., CombiWISE, EDSS and NeurEx), we
347	observed stronger effect sizes for unadjusted models (Figure 6A and Supplementary Table S2).
348	But for SDMT, the confounder-adjusted model slightly outperformed the unadjusted model.
349	
350	This hierarchy between models was generally preserved in the training cohort 10-fold cross-
351	validation results, shown in Figure 6A as violin plots with medians marked by red cross-
352	sectional line. Cross-validation have broad distribution of effect sizes in comparison to the full
353	training cohort: e.g., while training cohort Spearman correlation coefficients (Rho) were higher
354	than 0.75 for all eight models, cross-validation results ranged from Rho 0.2 to Rho 0.8,
355	showcasing the poor estimate of model's performance depending on the training cohort splits.
356	Nevertheless, cross-validation medians had uniformly lower effect sizes than the training cohort;
357	the decrease in effect sizes was substantial (between 40-60% for R^2).
358	
359	The independent validation cohort achieved effect sizes consistently below the cross-validation
360	medians, showcasing that the training cohort, including training cohort cross-validation,
361	significantly over-estimate models' performance. Nevertheless, all eight models validated with
362	very low p-values (all below 9E-8; Supplementary Table S2).
363	
364	The most surprising observation was that confounder-adjusted models consistently outperformed
365	models from unadjusted features in the independent validation cohort. The absolute difference in
366	R^2 values between unadjusted and adjusted models was up to R^2=0.08 (i.e., EDSS unadjusted
367	model achieved R^2=0.18, while adjusted model had R^2=0.26; Supplementary Table S2). This
368	represents relative improvement of 30%.

370	We conclude that training cohort results are poor predictors of the model's performance in the
371	independent validation cohort: they consistently and dramatically over-estimate final effect sizes.
372	The stronger validation performance of confounder-adjusted models supports our hypothesis that
373	effects of aging and other physiological covariates on MRI volumes represents noise when
374	predicting which MS-related CNS tissue damage contributes to clinical disability.
375	
376	This does not indicate that age does not play role in MS. In fact, age was selected as the strongest
377	feature in all confounder-adjusted models (Figure 6B), implying that age is the most important
378	determinant of MS-related disability. Our results simply support the hypothesis that age exerts
379	effects on CNS structures by (mostly) different mechanisms in physiological aging and in MS.
380	By separating the effect of age on MS from its effect on brain structures during natural aging, we
381	built more reliable models that predict MS-associated disability with higher effect sizes in the
382	independent validation cohort.
383	
384	4. DISCUSSION
385	The goal of this project was to gain understanding of MS-driven volumetric MRI changes and to
386	examine if computational models of confounder-adjusted MRI volumes reproducibly predict
387	different clinical outcomes.
388	
389	Before we discuss our findings, we want to point out following limitations: our HV cohort is
390	relatively small and the Lesion-TOADS automated segmentation algorithm, implemented from
391	the inception of our natural history protocol, has relatively narrow adoption. Despite the

392 differences in cohort sizes and the segmentation algorithms, our observations are aligned with 393 published literature, both for HV (Potvin et al., 2016) and MS (Ontaneda et al., 2021; Simpson-394 Yap et al., 2021). Specifically, although we tested six confounders, only age (and age^2), gender 395 and total intracranial volume influenced volumetric brain MRI features with effect sizes 396 comparable to those reported by others (Potvin et al., 2016). Second, we did not examine the 397 interaction between confounders because others (Potvin et al., 2016) found that these had 398 negligible effects. To facilitate broader use and potential external validation of our results, we 399 collaborated with QMENTA to implement publicly available Lesion-TOADS algorithm on their 400 platform. The other important limitation is that by the virtue of being national referral center, our 401 patient population may be skewed towards subject with more aggressive disease. However, this 402 limitation applies to all MS imaging studies, as these are performed almost uniformly in tertiary 403 academic centers. Finally, our comparably high effect sizes in predicting MS disability could be, 404 at least partially due to lower technical variability by virtue of a single center study that uses 405 standardized scanning protocols. Indeed, MAGNIMS investigators reported that inter-406 scanner/protocol confounders may explain >10% of variance (Cole et al., 2020). 407 408 Notwithstanding these limitations, our study achieved its aims. Our GBM models from 409 confounder-adjusted MRI features predicted four MS disability scales with high statistical 410 significance and good effect sizes in the independent validation cohort. These models slightly 411 outperformed analogous models derived from unadjusted MRI features and significantly 412 outperformed any single MRI biomarker.

413

414	Considering that approximately 50% of variance in brain volumes can be explained by
415	confounders, subtracting these confounders significantly diminished the difference between MS
416	and HV cohorts (which differed in age) and decreased univariate correlations with MS clinical
417	outcomes (which positively correlate with age). Ignoring such large effects of confounders on
418	MRI volumes overestimates how well the measured change reflects MS progression.
419	
420	Unexpectedly, confounder adjustment increased effect sizes (and lowered p-values) for WM
421	MRI volumes: for both supratentorial WM and normal appearing WM (which correlate strongly
422	with each other), but also for cerebellum WM, where the improvement was marginal. The
423	confounder-adjusted WM volumes had comparable effect size to BPFr in differentiating MS
424	from HV.
425	
425 426	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM
425 426 427	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM
425 426 427 428	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM structures and enlargement of ventricles) is the dominant effect of MS visible on conventional
425 426 427 428 429	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM structures and enlargement of ventricles) is the dominant effect of MS visible on conventional brain MRI. The resulting correlation matrix of confounder-adjusted MRI volumes supports this
425 426 427 428 429 430	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM structures and enlargement of ventricles) is the dominant effect of MS visible on conventional brain MRI. The resulting correlation matrix of confounder-adjusted MRI volumes supports this conclusion by demonstrating relatedness of MS-induced changes in all aforementioned
425 426 427 428 429 430 431	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM structures and enlargement of ventricles) is the dominant effect of MS visible on conventional brain MRI. The resulting correlation matrix of confounder-adjusted MRI volumes supports this conclusion by demonstrating relatedness of MS-induced changes in all aforementioned structures. Similarly, we saw that these brain structures were selected by most GBM models,
425 426 427 428 429 430 431 432	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM structures and enlargement of ventricles) is the dominant effect of MS visible on conventional brain MRI. The resulting correlation matrix of confounder-adjusted MRI volumes supports this conclusion by demonstrating relatedness of MS-induced changes in all aforementioned structures. Similarly, we saw that these brain structures were selected by most GBM models, with predictably higher influence of WM volumes in the models based on confounder-adjusted
425 426 427 428 429 430 431 432 433	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM structures and enlargement of ventricles) is the dominant effect of MS visible on conventional brain MRI. The resulting correlation matrix of confounder-adjusted MRI volumes supports this conclusion by demonstrating relatedness of MS-induced changes in all aforementioned structures. Similarly, we saw that these brain structures were selected by most GBM models, with predictably higher influence of WM volumes in the models based on confounder-adjusted biomarkers.
425 426 427 428 429 430 431 432 433 434	We conclude that after subtracting the effects of natural aging and sexual dimorphism, WM pathology (represented by formation of MS lesions associated with atrophy of deep GM structures and enlargement of ventricles) is the dominant effect of MS visible on conventional brain MRI. The resulting correlation matrix of confounder-adjusted MRI volumes supports this conclusion by demonstrating relatedness of MS-induced changes in all aforementioned structures. Similarly, we saw that these brain structures were selected by most GBM models, with predictably higher influence of WM volumes in the models based on confounder-adjusted biomarkers.

436 important in GBM models of disability, this was not true for SC CSA. C1-2 SC CSA had

437	marginal effect size and p-value in differentiating MS from HV, but it had relatively high
438	univariate correlations with disability outcomes and, concordantly, was selected by all GBM
439	models of physical disability (i.e., EDSS, CombiWISE, and NeurEx) as leading MRI feature.
440	These results are consistent with clinical observations that MS involvement of SC is the
441	dominant driver of physical disability, especially ambulation. We believe that relatively weak
442	effect size in differentiating MS from HV for SC CSA resides in the technical difficulty of
443	scanning such small structure. We did not have dedicated SC MRIs for most subjects, and
444	artifacts due to CSF pulsation, heart beats and breathing are likely accentuated by using brain
445	coil, rather than dedicated SC coil with protocol optimized for SC imaging.
446	
447	Additionally, age was selected as the strongest variable in confounder-adjusted models. This
448	poses a question whether we gained anything by adjusting MRI features for confounders. First,
449	confounder adjustment did enhance validation performance of the models. Second, in unilateral
450	correlations, age correlates with disability outcomes with effect sizes comparable to strongest
451	MRI biomarkers. However, this does not mean that effect of age on MS disability is
452	pathophysiologically identical to normal aging. For example, age effects on immunity may
453	become relevant only in patients with intrathecal inflammation. Separating age from its
454	confounding effect on MRI biomarkers may lead to models that are more responsive to MS
455	treatment effects, a potential hypothesis for future longitudinal studies.
456	
457	Thanks to a recent meta-analysis of 302 papers describing models of MS clinical outcomes (Liu
458	et al., 2022), we can compare our results with other published MRI biomarker-based models.
459	Using an associated website that allow users to dynamically explore this rich dataset, we

460 identified 40 papers that used MRI biomarkers to model EDSS as ordinal scale and reported p-461 values, and 20 papers that reported effect sizes as R^2. Many studies overestimate effect sizes 462 from using small cohorts or failing to implement methodological design that limit bias (Button et 463 al., 2013; Ioannidis, 2005, 2008). Thus, the meta-analysis scored methodological rigor of reviewed studies by grading 7 criteria: 1. Blinding, 2. Defined strategy to deal with outliers, 3. 464 465 Explanation of missingness, 4. Adjustment for confounders, 5. Number of comparisons made 466 and whether p-values were adjusted, 6. Presence of controls and 7. Validation (cross-validation 467 of the training cohort versus independent validation cohort). The median numbers of criteria 468 fulfilled by published studies that modelled EDSS was 2, and the majority studied less than 100 MS patients. Only 38% of studies adjusted p-values for multiple comparisons, and studies that 469 470 did not adjust performed up to 500 comparisons. The studies with the highest methodological 471 rigor and largest cohorts originated from the MAGNIMS consortium. MAGNIMS study of 472 effects of GM brain volumes on differentiating MS (n=961) from HV (n=203) and on disability 473 prediction found negative association between deep GM ( $\beta$ =-0.71; p<0.0001) and cortical GM 474  $(\beta = -0.22; p < 0.0001)$  and EDSS. Unfortunately, R<sup>2</sup> was not reported. For much smaller studies 475 that reported R<sup>2</sup>, the range was 0.7 to 0.05 in the training cohort. Only one study reported crossvalidation/OOB results (Cordani et al., 2021) and achieved R^2=0.19 (p-value range from 476 477 <0.001 to 0.04) in RRMS (n=250) and R<sup>2</sup>=0.16 (p-value range from 0.02 to 0.04) in PMS 478 (n=114). Current study fulfills 7/7 criteria of methodological rigor and is the only study that 479 includes independent validation cohort. For the confounder-adjusted EDSS model, the training 480 cohort  $\mathbb{R}^2$  is 0.69 (p=3.8e-43). Median cross-validation  $\mathbb{R}^2$  is 0.29 and the independent 481 validation cohort R<sup>2</sup> is 0.26 (p=2.4e-08). To our knowledge, this is the strongest reported effect

482 size for predicting EDSS as ordinal scale from quantitative MRI biomarkers in the literature thus483 far.

484

485 Analogously, we identified 12 studies that used MRI predictors for modeling SDMT. 11/12

486 reported p-values and 5/12 reported R^2. The median methodological rigor score was 2/7 and

487 most cohorts were smaller than 100 subjects (the largest had 151 subjects). Only 16.7% adjusted

488 for multiple comparisons and the studies that did not adjust p-values performed up to 100

489 comparisons. No studies reported cross-validation or independent validation. The reported R^2

490 (for the training cohorts) ranged from 0.62-0.3. Again, our confounder-adjusted SDMT model

491 achieved  $R^2=0.78$  (p=7.3e-75) with independent validation  $R^2=0.34$  (p=2.9e-11), which

492 represent the best performance among published studies.

493

494 We have observed that cross-validation generates broad range of results that encompass the 495 effect sizes of the independent validation cohort, but the median of cross-validation results is still 496 overly optimistic. This is consistent with our extensive observations using independent validation 497 in all our projects (Boukhvalova et al., 2019; Liu et al., 2022; Masvekar et al., 2021; Messan et 498 al., 2022; Pham et al., 2021). Therefore, while cross-validation should be included in all 499 modeling studies, the independent validation must be considered a gold standard. This is 500 extremely important, as only 15% of published MS models used any validation strategy and only 501 8% used independent validation.

502

503 In conclusion, our final models outperform correlations of any single MRI biomarker with

clinical outcomes. These models are therefore likely more sensitive imaging outcomes and

- should be explored in future clinical trials, especially when targeting older subjects with
- 506 progressive MS who no longer form acute MS lesions. The MAGNIMS consortium has available
- 507 datasets to quantify possible loss of sensitivity due to inter-scanner/inter-protocol variance on
- such ML-based models in comparison to a single MRI biomarker.

### 509 FIGURE LEGENDS



Figure 1. Study design. 1: All subjects participating in a prospective collection of standardized 511 512 clinical and imaging outcomes under a natural history protocol for 20 years were enrolled. 2: All subjects underwent full neurological examination transcribed to the NeurEx<sup>TM</sup> App that 513 514 automatically calculates clinician-derived disability scales. Additional functional tests, such as 515 Symbol Digit Modalities Test (SDMT) and stated confounding factors were collected and transcribed to research database. 3: All subjects underwent research brain MRI that extended 516 517 caudally to the C5 level of the spinal cord (SC). 4: Anonymized MRIs were uploaded to the 518 cloud-based QMENTA platform to derive brain volumetric data using Lesion-TOADS 519 algorithm. Upper cervical SC C1-C2 volume was calculated using Spinal Cord Toolbox. 5: 520 Resulting quantitative MRI biomarkers were assessed for quality to identify intra- and inter-521 individual outliers. Identified outliers were manually checked and scans with incorrect

522	segmentation were excluded $(122/771 = 15.8\%)$ . <b>6:</b> Unblinding of diagnostic categories occurred
523	after exclusion of technical outliers was completed. 7: We regressed out the effects of six stated
524	confounders measured in the HV cohort (n=80) and applied the same transformation to non-MS
525	(n=100) and MS (n=409) cohorts to eliminate effects of physiological confounders on MRI
526	volumes. 8: We validated lack of residual correlations with the confounding factors in non-MS
527	cohort. <b>9:</b> MS patients were randomly split into training (n=277) and validation (n=132) cohorts
528	using stratified split to assure equal proportions of gender and MS types in both cohorts. 10:
529	Gradient boosting machine (GBM) algorithm was applied to the training cohort using
530	confounder-adjusted (and unadjusted) MRI features as predictors to derive two sets of models for
531	the four stated clinical outcomes. 11: Models were further optimized in the training cohort using
532	10-fold cross validation. 12: Resulting eight models were applied to the independent validation
533	cohort that did not contribute, in any way, to the generation or optimization of the models.

### Ventricular CSF Adjustment



Figure 2. Example of the adjustment of single MRI biomarker (i.e., ventricular CSF
volume) for six physiological confounders. A. The final equation for the confounder-adjusted
ventricular volume is shown at the top of the Figure in red outline. This equation was derived
from multiple linear regression models as described in the Method section. B. In the top right
corner is resulting radar chart that show proportional weights of the applied confounder
adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros.
C. Univariate linear regression models between each tested confounder on x-axis (first 5 graphs)

534

- 542 or gender (sixth graph) and measured ventricular volume on the y-axis in 80 healthy volunteers
- 543 (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show
- 544 no remaining effect of confounders. E. Applying HV-derived adjustment formula to MS cohort
- shows remaining significant residual effect of age, when considering Bonferroni adjustment for
- 546 multiple comparisons (i.e., p < 0.05/12 = p < 0.004). Analogous Figures showing adjustment for all
- 547 MRI features are in the Supplementary information.



### Differences Between HV and MS in MRI Features

548

MRI features where confounder-adjustment WORSENED or IMPROVED difference between MS and HV cohort

549 Figure 3. Effect of adjustment for physiological confounders on measured differences in 550 MRI volumetric features between HV and MS patients. Right side of the figure shows effect sizes of unadjusted (gray bars) and confounder-adjusted (green bars) volumetric MRI features to 551 552 differentiate MS from HV. Effect sizes are shown as Standardized Main Difference (i.e., 553 Cohen's d). Left side of the figure shows the effect of applied confounder adjustment with log p-

554 value. MRI features where confounder adjustment decreased the difference between MS and HV

555 are highlighted in blue, whereas those MRI features where confounder adjustment increased the

difference are highlighted in red. 11 out of 15 MRI features differentiated MS from HV with 556

557 statistical significance. The difference between MS and HV was partially driven by confounder

- differences in majority of these MRI features (6/10). Thus, the applied adjustment decreased the 558
- 559 ability of these features to differentiate MS from HV. On the other hand, three measurements of

- 560 white matter volume (supratentorial WM, normal-appearing WM and cerebellum WM) enhanced
- their ability to differentiate MS from HV after confounder adjustment.



# **Correlation Matrix for Volumetrics**



562

- 569 correlations of MRI features with age, while it generally strengthened correlations of brain
- 570 parenchymal fraction (BPFr) with remaining MRI features.

# **Univariate Spearman Correlation Coefficients**



### 572 Figure 5. Unilateral correlation matrix of unadjusted and confounder-adjusted MRI

571

573 features with disability outcomes. The top row shows unilateral correlations of disability

574 outcomes with unadjusted MRI features. Left panel shows correlations of MS training cohort and

575 right panel shows correlations of MS validation cohort. Bottom row shows analogous

576 correlations with confounder-adjusted MRI features. Correlations that are not statistically

- 577 significant are marked as (ns). Positive correlations are marked in red and negative in blue
- colors. Correlation p-values indicate statistical significance (\*P < 0.05, \*\*P < 0.01, and \*\*\*P < 0.01, \*P < 0.0
- 579 0.001). Additional descriptive statistics are shown in Supplementary Table S1.



581 Figure 6. Summary of model performances. A. The left panel shows Spearman Rho 582 correlation coefficients while right panel shows coefficient of determination (R^2) for the same 8 583 models. For each outcome (arranged in vertical columns), the unadjusted models are on the left 584 side outlined in black, and the confounder-adjusted models are on the right side, outlined in 585 green. The model performance in the training cohort is shown as circle; the distribution of cross-586 validation (i.e., re-using of the training cohort) results is shown as a violin plot with the median 587 marked as a red horizontal line; the independent validation cohort performance is shown as 588 diamond. The size of the symbols (i.e., circle and diamond) correspond to the Linh's 589 concordance coefficient (CCC). Finally, the color of each symbol represents p-value (-log10) with lower p-values displayed in purple color and higher p-values in orange in accordance with 590 591 the heatmap displayed in the figure legend. Unequivocal and robust decrease in model's 592 performance is seen from training cohort to cross-validation to independent validation. Detailed 593 statistics of the model performances are shown in Supplementary Table S2. 594 **B.** For each clinical outcome modelled (presented in rows) we show number of features selected 595 in the final model(s) arranged in descending order of variable importance. The unadjusted 596 models are displayed on the left, while confounder-adjusted models are displayed on the right.

### 597 **REFERENCES**

- Amin, M., Ontaneda, D., 2021. Thalamic Injury and Cognition in Multiple Sclerosis. Frontiers in
  Neurology 11.
- Barbour, C., Kosa, P., Varosanec, M., Greenwood, M., Bielekova, B., 2020. Molecular models
- of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms. medRxiv,
- **602** 2020.2005.2018.20105932.
- 603 Benedict, R.H., DeLuca, J., Phillips, G., LaRocca, N., Hudson, L.D., Rudick, R., 2017. Validity
- of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple
- sclerosis. Multiple Sclerosis Journal 23, 721-733.
- 606 Boukhvalova, A.K., Fan, O., Weideman, A.M., Harris, T., Kowalczyk, E., Pham, L., Kosa, P.,
- 607 Bielekova, B., 2019. Smartphone Level Test Measures Disability in Several Neurological
- 608 Domains for Patients With Multiple Sclerosis. Frontiers in Neurology 10.
- 609 Button, K.S., Ioannidis, J.P., Mokrysz, C., Nosek, B.A., Flint, J., Robinson, E.S., Munafo, M.R.,
- 610 2013. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev
- 611 Neurosci 14, 365-376.
- 612 Cole, J.H., Raffel, J., Friede, T., Eshaghi, A., Brownlee, W.J., Chard, D., De Stefano, N.,
- 613 Enzinger, C., Pirpamer, L., Filippi, M., Gasperini, C., Rocca, M.A., Rovira, A., Ruggieri, S.,
- 614 Sastre-Garriga, J., Stromillo, M.L., Uitdehaag, B.M.J., Vrenken, H., Barkhof, F., Nicholas, R.,
- 615 Ciccarelli, O., group, M.s., 2020. Longitudinal Assessment of Multiple Sclerosis with the Brain-
- 616 Age Paradigm. Ann Neurol 88, 93-105.
- 617 Cole, J.H., Underwood, J., Caan, M.W., De Francesco, D., van Zoest, R.A., Leech, R., Wit,
- 618 F.W., Portegies, P., Geurtsen, G.J., Schmand, B.A., Schim van der Loeff, M.F., Franceschi, C.,

- 619 Sabin, C.A., Majoie, C.B., Winston, A., Reiss, P., Sharp, D.J., collaboration, C., 2017. Increased
- brain-predicted aging in treated HIV disease. Neurology 88, 1349-1357.
- 621 Cordani, C., Hidalgo de la Cruz, M., Meani, A., Valsasina, P., Esposito, F., Pagani, E., Filippi,
- 622 M., Rocca, M.A., 2021. MRI correlates of clinical disability and hand-motor performance in
- 623 multiple sclerosis phenotypes. Mult Scler 27, 1205-1221.
- 624 De Leener, B., Lévy, S., Dupont, S.M., Fonov, V.S., Stikov, N., Louis Collins, D., Callot, V.,
- 625 Cohen-Adad, J., 2017. SCT: Spinal Cord Toolbox, an open-source software for processing spinal
- 626 cord MRI data. NeuroImage 145, 24-43.
- 627 Greenwell, B., Boehmke, B., Cunningham, J., Developers, G., 2020. gbm: Generalized Boosted
- 628 Regression Models.
- 629 Hemond, C.C., Bakshi, R., 2018. Magnetic Resonance Imaging in Multiple Sclerosis. Cold
- 630 Spring Harbor perspectives in medicine 8, a028969.
- 631 Ioannidis, J.P., 2005. Why most published research findings are false. PLoS Med 2, e124.
- Ioannidis, J.P., 2008. Why most discovered true associations are inflated. Epidemiology 19, 640-633 648.
- Jacobs, S.A.H., Muraro, P.A., Cencioni, M.T., Knowles, S., Cole, J.H., Nicholas, R., 2021.
- 635 Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory T-Cells
- 636 in Multiple Sclerosis Patients With Older Appearing Brains. Front Neurol 12, 801097.
- 637 Jakimovski, D., Zivadinov, R., Weinstock-Guttman, B., Bergsland, N., Dwyer, M.G., Lagana,
- 638 M.M., 2020. Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow
- 639 changes driven by brain atrophy. Fluids and barriers of the CNS 17, 9-9.
- 640 Kassambara, A., 2021. rstatix: Pipe-Friendly Framework for Basic Statistical Tests.

- 641 Kosa, P., Barbour, C., Wichman, A., Sandford, M., Greenwood, M., Bielekova, B., 2018.
- 642 NeurEx: digitalized neurological examination offers a novel high-resolution disability scale.
- 643 Annals of Clinical and Translational Neurology 5, 1241-1249.
- 644 Kurtzke, J.F., 1983. Rating neurologic impairment in multiple sclerosis. An expanded disability
- 645 status scale (EDSS) 33, 1444-1444.
- Liu, J., Kelly, E., Bielekova, B., 2022. Current status and future opportunities in modeling
- 647 Multiple Sclerosis clinical characteristics. medRxiv, 2022.2002.2024.22271474.
- 648 Masvekar, R., Phillips, J., Komori, M., Wu, T., Bielekova, B., 2021. Cerebrospinal Fluid
- 649 Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis
- 650 Lesional Inflammatory Activity. Frontiers in Neuroscience 15.
- 651 Messan, K.S., Pham, L., Harris, T., Kim, Y., Morgan, V., Kosa, P., Bielekova, B., 2022.
- 652 Assessment of Smartphone-Based Spiral Tracing in Multiple Sclerosis Reveals Intra-Individual
- 653 Reproducibility as a Major Determinant of the Clinical Utility of the Digital Test. Frontiers in
- 654 Medical Technology 3.
- 655 Ontaneda, D., Sati, P., Raza, P., Kilbane, M., Gombos, E., Alvarez, E., Azevedo, C., Calabresi,
- 656 P., Cohen, J.A., Freeman, L., Henry, R.G., Longbrake, E.E., Mitra, N., Illenberger, N., Schindler,
- 657 M., Moreno-Dominguez, D., Ramos, M., Mowry, E., Oh, J., Rodrigues, P., Chahin, S., Kaisey,
- M., Waubant, E., Cutter, G., Shinohara, R., Reich, D.S., Solomon, A., Sicotte, N.L., 2021.
- 659 Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a
- 660 prospective multicenter trial. NeuroImage: Clinical 32, 102834.
- 661 Pham, L., Harris, T., Varosanec, M., Morgan, V., Kosa, P., Bielekova, B., 2021. Smartphone-
- based symbol-digit modalities test reliably captures brain damage in multiple sclerosis. npj
- 663 Digital Medicine 4, 36.

- 664 Potvin, O., Mouiha, A., Dieumegarde, L., Duchesne, S., Alzheimer's Disease Neuroimaging, I.,
- 665 2016. Normative data for subcortical regional volumes over the lifetime of the adult human
- 666 brain. Neuroimage 137, 9-20.
- 667 Rocca, M.A., Battaglini, M., Benedict, R.H.B., De Stefano, N., Geurts, J.J.G., Henry, R.G.,
- 668 Horsfield, M.A., Jenkinson, M., Pagani, E., Filippi, M., 2017. Brain MRI atrophy quantification
- in MS: From methods to clinical application. Neurology 88, 403-413.
- 670 Shiee, N., Bazin, P.-L., Ozturk, A., Reich, D.S., Calabresi, P.A., Pham, D.L., 2010. A topology-
- 671 preserving approach to the segmentation of brain images with multiple sclerosis lesions.
- 672 NeuroImage 49, 1524-1535.
- 673 Signorell, A., Aho, K., Alfons, A., Anderegg, N., Aragon, T., Arachchige, C., Arppe, A.,
- Baddeley, A., Barton, K., Bolker, B., Borchers, H.W., Caeiro, F., Champely, S., Chessel, D.,
- 675 Chhay, L., Cooper, N., Cummins, C., 2021. DescTools: Tools for Descriptive Statistics.
- 676 Simpson-Yap, S., De Brouwer, E., Kalincik, T., Rijke, N., Hillert, J.A., Walton, C., Edan, G.,
- 677 Moreau, Y., Spelman, T., Geys, L., Parciak, T., Gautrais, C., Lazovski, N., Pirmani, A.,
- Ardeshirdavanai, A., Forsberg, L., Glaser, A., McBurney, R., Schmidt, H., Bergmann, A.B.,
- Braune, S., Stahmann, A., Middleton, R., Salter, A., Fox, R.J., van der Walt, A., Butzkueven, H.,
- 680 Alroughani, R., Ozakbas, S., Rojas, J.I., van der Mei, I., Nag, N., Ivanov, R., Sciascia do Olival,
- 681 G., Dias, A.E., Magyari, M., Brum, D., Mendes, M.F., Alonso, R.N., Nicholas, R.S., Bauer, J.,
- 682 Chertcoff, A.S., Zabalza, A., Arrambide, G., Fidao, A., Comi, G., Peeters, L., 2021. Associations
- of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology 97,
- 684 e1870-e1885.
- Team, R., 2015. RStudio: Integrated Development for R. RStudio, Inc.
- 686 Team, R.C., 1969. stats package RDocumentation.

- 687 Team, R.C., 2021. R: A Language and Environment for Statistical Computing. R Foundation for
- 688 Statistical Computing, <u>https://www.R-project.org/</u>, Vienna, Austria.
- 689 Weideman, A.M., Barbour, C., Tapia-Maltos, M.A., Tran, T., Jackson, K., Kosa, P., Komori, M.,
- 690 Wichman, A., Johnson, K., Greenwood, M., Bielekova, B., 2017a. New Multiple Sclerosis
- 691 Disease Severity Scale Predicts Future Accumulation of Disability. Frontiers in Neurology 8.
- 692 Weideman, A.M., Tapia-Maltos, M.A., Johnson, K., Greenwood, M., Bielekova, B., 2017b.
- 693 Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front Neurol 8,
- **694** 577.
- 695 Zeydan, B., Kantarci, O.H., 2020. Impact of Age on Multiple Sclerosis Disease Activity and
- 696 Progression. Curr Neurol Neurosci Rep 20, 24.

697